Anemia Clinical Trials

Find Anemia Clinical Trials Near You

Effect of Direct Fetal Intravenous Immunoglobulin Administration During Intrauterine Transfusion on Neonatal Outcomes in Rhesus Isoimmunised Pregnancies: A Randomized Controlled Trial

Status: Recruiting
Location: See location...
Intervention Type: Drug, Procedure
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The goal of this clinical trial is to learn if giving intravenous immunoglobulin directly to the fetus during intrauterine transfusion can improve newborn outcomes in pregnancies affected by rhesus isoimmunization. Rhesus isoimmunization happens when a pregnant woman's immune system attacks her baby's red blood cells. This can cause severe anemia (low red blood cell levels) before birth. Doctors treat this condition with intrauterine transfusion, a procedure that gives blood to the fetus before birth. However, this treatment does not stop the immune attack. Many newborns still develop anemia and high bilirubin levels after birth and may need phototherapy or exchange transfusion. The main questions this study aims to answer are: Does adding fetal intravenous immunoglobulin increase the baby's blood count at birth? Does it lower the need for phototherapy or exchange transfusion after birth? Researchers will compare: Intrauterine transfusion with fetal intravenous immunoglobulin to Intrauterine transfusion alone to see if adding immunoglobulin improves newborn outcomes. Participants will: * Undergo intrauterine transfusion as part of routine care * Be randomly assigned to receive either standard transfusion alone or transfusion with added fetal immunoglobulin * Be followed until delivery and during the newborn hospital stay The main outcome is the baby's blood count at birth. Researchers will also measure: * How quickly the baby's blood count falls before birth * Need for and duration of phototherapy * Need for exchange transfusion or blood transfusions after birth * Any procedure-related complications This study will help determine whether treating the immune process before birth can improve health outcomes for newborns affected by rhesus isoimmunization.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 4 months
Healthy Volunteers: f
View:

• Rh isoimmunized mother-fetus dyads undergoing first clinically indicated intrauterine transfusion

• Gestational age 20 weeks or more at the time of first intrauterine transfusion

• Written informed consent obtained from parent(s) or legal guardian

Locations
Other Locations
India
PGIMER
RECRUITING
Chandigarh
Contact Information
Primary
Sourabh Dutta, MD, Ph.D
sourabhdutta1@gmail.com
+91 172 2724053
Backup
Vishnu Somakumar, MBBS, MD
vishnusomakumar@gmail.com
+91 9791674117
Time Frame
Start Date: 2026-05-25
Estimated Completion Date: 2027-07
Participants
Target number of participants: 30
Treatments
Active_comparator: Standard Intrauterine Transfusion
Participants will undergo intrauterine transfusion using compatible packed red blood cells as per institutional protocol. No intravenous immunoglobulin will be administered to the fetus.
Experimental: Intrauterine Transfusion With Direct Fetal Intravenous Immunoglobulin
Participants will undergo standard intrauterine transfusion followed by intravascular administration of intravenous immunoglobulin directly into the fetal circulation during the same procedure.
Sponsors
Leads: Post Graduate Institute of Medical Education and Research, Chandigarh

This content was sourced from clinicaltrials.gov